Biomarkers for lung adenocarcinoma (LUAD), and method for treating luad

TW202637844APending Publication Date: 2026-09-16VETERANS GEN HOSPITAL TAIPEI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114108793
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Filing Date
2025-03-10
Publication Date
2026-09-16

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present invention provides a method for predicting clinical outcomes of a lung cancer patient, such as LUAD, particularly LUAD with low expression of NKX2-1. Also provided includes a use of inhibitor of CXCR2 in manufacturing a medicament for treating lung adenocarcinoma (LUAD). The present invention provides a strategy of treatment to suppress tumorigenesis and improve the survival outcome of LUAD patients with NKX2-1-low malignant tumors through targeting the NKX2-1 / CXC chemokine signaling.
Need to check novelty before this filing date? Find Prior Art